Els Verdegaal

15PUBLICATIONS
67CO-AUTHORS
Innate immunityPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 18, 2026
Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy.

|Jun 24, 2026
Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

|May 06, 2025
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα.

Els M E Verdegaal, Anique L C Verpoorte, Monique K van der Kooij

|Jun 30, 2024
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman

|Jan 09, 2024
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.

Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen

|Nov 10, 2023
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.

Els M E Verdegaal, Saskia J Santegoets, Marij J P Welters

Pageof 3

Frequent Collaborators

10 joint publications

Sjoerd H van der Burg

6 joint publications

Ellen Kapiteijn

4 joint publications

Noel F C C de Miranda

3 joint publications

Saskia J Santegoets